SCHEMBL10084841

SCHEMBL10084841

CCOC(=O)C(C)n1c(=O)[nH]c2ccc(C)cc2c1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.47
▸ KDM4E B2RXH2 6/20 0.47
▸ SMN1; SMN2 Q16637 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ GAA P10253 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ NPC1 O15118 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ PABPC1 P11940 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ KMT2A Q03164 4/20 0.43
▸ MEN1 O00255 3/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ HSD17B10 Q99714 2/20 0.41
▸ HPGD P15428 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10084835 0.89 ALDH1A1 (0.44) ALDH1A1KDM4ESMN1; SMN2MAPTGAA
SCHEMBL10085586 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTGAANPC1
SCHEMBL10085100 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EMAPTGAANPC1
SCHEMBL10086146 0.83 GAA (0.42) ALDH1A1KDM4ESMN1; SMN2MAPTGAA
SCHEMBL10084830 0.83 MEN1 (0.44) ALDH1A1KDM4ESMN1; SMN2MAPTGAA
SCHEMBL10084832 0.81 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTGAANPC1
SCHEMBL10085638 0.81 MEN1 (0.48) ALDH1A1KDM4EMAPTGAAKMT2A
SCHEMBL19254886 0.81 MEN1 (0.48) ALDH1A1KDM4EMAPTGAAKMT2A
SCHEMBL10085072 0.81 ALDH1A1 (0.41) ALDH1A1KDM4EMAPTGAANPC1
SCHEMBL10085008 0.80 ALDH1A1 (0.49) ALDH1A1KDM4ESMN1; SMN2MAPTGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 ALDH1A1 3536/4885KDM4E 633/4885SMN1; SMN2 3062/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback